Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Boehringer Ingelheim
AstraZeneca
Baxter
McKesson

Last Updated: August 17, 2022

Investigational Drug Information for Trehalose


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug Trehalose?

Trehalose is an investigational drug.

There have been 17 clinical trials for Trehalose. The most recent clinical trial was a Phase 2 trial, which was initiated on November 9th 2021.

The most common disease conditions in clinical trials are Alzheimer Disease, Macular Edema, and Keratoconjunctivitis Sicca. The leading clinical trial sponsors are Mashhad University of Medical Sciences, Seelos Therapeutics, Inc., and Bioblast Pharma Ltd.

There are four hundred and thirty US patents protecting this investigational drug and twenty-nine international patents.

Recent Clinical Trials for Trehalose
TitleSponsorPhase
SLS-005 (Trehalose Injection) in the Treatment of Alzheimer's DiseaseSeelos Therapeutics, Inc.Phase 2
SLS-005 (Trehalose Injection) in the Treatment of Alzheimer's DiseaseNeuroscience Trials AustraliaPhase 2
Efficacy of Oral Administration of Trehalose in Patients With Parkinson DiseaseNeuromed IRCCSPhase 4

See all Trehalose clinical trials

Clinical Trial Summary for Trehalose

Top disease conditions for Trehalose
Top clinical trial sponsors for Trehalose

See all Trehalose clinical trials

US Patents for Trehalose

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Trehalose See Plans and Pricing Phosphonate compounds for treatment of medical disorders Achillion Pharmaceuticals, Inc. (New Haven, CT) See Plans and Pricing
Trehalose See Plans and Pricing Double-acylated GLP-1 derivatives Novo Nordisk A/S (Bagsvaerd, DK) See Plans and Pricing
Trehalose See Plans and Pricing Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer Capella Therapeutics, Inc. (San Diego, CA) See Plans and Pricing
Trehalose See Plans and Pricing Polymeric nanoparticles and methods of making and using same Merck Sharp & Dohme Corp. (Rahway, NJ) Pfizer Inc. (New York, NY) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Trehalose

Drugname Country Document Number Estimated Expiration Related US Patent
Trehalose World Intellectual Property Organization (WIPO) WO2013170005 2032-05-11 See Plans and Pricing
Trehalose Taiwan TW201718611 2035-08-26 See Plans and Pricing
Trehalose World Intellectual Property Organization (WIPO) WO2017035357 2035-08-26 See Plans and Pricing
Trehalose China CN104519902 2032-05-08 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Boehringer Ingelheim
AstraZeneca
Baxter
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.